Interestingly, drug-sensitive cells from both NSCLC and CML models showed higher levels of flotillin-1, a protein enriched in lipid rafts (NSCLC: 1.00 ± 0.0 vs. 0.19 ± 0.06, p ≤ 0.05; CML: 1.00 ± 0.0 vs. 0.32 ± 0.17, p ≤ 0.05) (Figure 4B). This evidence concerns the gene FLOT1 and chronic myelogenous leukemia, BCR-ABL1 positive.